The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.
Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance
Open accessAbstract
Quinolone antimicrobials are widely used in clinical medicine and are the only current class of agents that directly inhibit bacterial DNA synthesis.Quinolones dually target DNA gyrase and topoisomerase IV binding to specific domains and conformations so as to block DNA strand passage catalysis and stabilize DNA -enzyme complexes that block the DNA replication apparatus and generate double breaks in DNA that underlie their bactericidal activity.Resistance has emerged with clinical use of these agents and is common in some bacterial pathogens.Mechanisms of resistance include mutational alterations in drug target affinity and efflux pump expression and acquisition of resistance-conferring genes.Resistance mutations in one or both of the two drug target enzymes are commonly in a localized domain of the GyrA and ParC subunits of gyrase and topoisomerase IV, respectively, and reduce drug binding to the enzyme-DNA complex.Other resistance mutations occur in regulatory genes that control the expression of native efflux pumps localized in the bacterial membrane(s).These pumps have broad substrate profiles that include other antimicrobials as well as quinolones.Mutations of both types can accumulate with selection pressure and produce highly resistant strains.Resistance genes acquired on plasmids confer low-level resistance that promotes the selection of mutational high-level resistance.Plasmid-encoded resistance is because of Qnr proteins that protect the target enzymes from quinolone action, a mutant aminoglycoside-modifying enzyme that also modifies certain quinolones, and mobile efflux pumps.Plasmids with these mechanisms often encode additional antimicrobial resistances and can transfer multidrug resistance that includes quinolones.Q uinolones have been used extensively for a wide range of clinical applications (Owens and Ambrose 2000; Kim and Hooper 2014).Nalidixic acid, a related naphthyridone structure and the first member of the class used clinically, was discovered by George Lesher as a byproduct of chloroquine synthesis in 1962.Its use was limited to treatment of urinary tract infections and resistance emerged quickly (Lesher et al. 1962).Medicinal chemists from a number of companies, however, subsequently modified the core quinolone and related chemical scaffolds, generating compounds with greater potency, broader spectra of activity, improved pharmacokinetics, and lower frequency of development of resistance (Domagala and Hagen 2003).An important addition of a fluorine substituent at position 6 added to po-Editors: Lynn L. Silver and Karen Bush
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One major contributor to fluoroquinolone resistance is the emergence of mutations in the grlA and gyrA genes, which encode subunits of topoisomerase IV and DNA gyrase, the primary targets of fluoroquinolones [242].”
From Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms (2025) · cites this paper as [242]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, J. C. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.003223 · Cited by 1,832
The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria
Li, X.-Z., Plésiat, P., & Nikaido, H. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-14 · Cited by 1,614
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica, K., & Zhao, X. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.3.377-392.1997 · Cited by 1,494
Mechanism of Quinolone Action and Resistance
Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282
Quinolone resistance from a transferable plasmid
Martínez-Martínez, L., Pascual, A., & Jacoby, G. A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07322-4 · Cited by 1,100
Self-citationFluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
Robicsek, A., Strahilevitz, J., Jacoby, G. A., Macielag, M., Abbanat, D., Hye Park, C., Bush, K., & Hooper, D. C. (2006) · Nature Medicine · doi:10.1038/nm1347 · Cited by 1,013
Self-citationEfflux-Mediated Drug Resistance in Bacteria: An Update
Li, X.-Z., & Nikaido, H. (2009) · Drugs · doi:10.2165/11317030-000000000-00000 · Cited by 966
Type IIA topoisomerase inhibition by a new class of antibacterial agents
Bax, B. D., Chan, P. F., Eggleston, D. S., Fosberry, A., Gentry, D. R., Gorrec, F., Giordano, I., Hann, M. M., Hennessy, A., Hibbs, M., et al. (2010) · Nature · doi:10.1038/nature09197 · Cited by 860
Efflux-Mediated Drug Resistance in Bacteria
Li, X.-Z., & Nikaido, H. (2004) · Drugs · doi:10.2165/00003495-200464020-00004 · Cited by 798
Molecular Properties of Bacterial Multidrug Transporters
Putman, M., van Veen, H. W., & Konings, W. N. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.4.672-693.2000 · Cited by 795
Cited by
Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects
Uddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., Dhama, K., Ripon, M. K. H., Gajdács, M., Sahibzada, M. U. K., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.10.020 · Cited by 1,311
Pham, T. D. M., Ziora, Z. M., & Blaskovich, M. A. T. (2019) · MedChemComm · doi:10.1039/c9md00120d · Cited by 785
Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms
Touaitia, R., Mairi, A., Ibrahim, N. A., Basher, N. S., Idres, T., & Touati, A. (2025) · Antibiotics · doi:10.3390/antibiotics14050470 · Cited by 273
Kent, A. G., Vill, A. C., Shi, Q., Satlin, M. J., & Brito, I. L. (2020) · Nature Communications · doi:10.1038/s41467-020-18164-7 · Cited by 216
Structural assembly of the bacterial essential interactome
Gómez Borrego, J., & Torrent Burgas, M. (2024) · eLife · doi:10.7554/elife.94919 · Cited by 16
Wei, J., Liu, C., Qin, D., Ren, F., Duan, J., Chen, T., & Wu, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102544 · Cited by 15
Metadata
- Authors
- Hooper, D. C., & Jacoby, G. A.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-07-22
- Volume
- 6
- Issue
- 9
- Pages
- a025320
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2498876603
- Cited by
- 553
- References
- 158
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.